Back to Journals » Neuropsychiatric Disease and Treatment » Volume 12

Suvorexant: a promising, novel treatment for insomnia

Authors Lee-Iannotti J, Parish J

Received 1 July 2015

Accepted for publication 19 August 2015

Published 25 February 2016 Volume 2016:12 Pages 491—495

DOI https://doi.org/10.2147/NDT.S31495

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Xiang Mou

Peer reviewer comments 4

Editor who approved publication: Dr Roger Pinder


Joyce K Lee-Iannotti,1 James M Parish2

1Division of Neurology, Sleep Disorders Center, Banner University Medical Center, Phoenix, AZ, USA; 2Division of Pulmonary Medicine, Center for Sleep Medicine, Mayo Clinic, Phoenix, AZ, USA

Abstract: Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Keywords: insomnia, orexin-receptor antagonist, CYP3A4, benzodiazepan receptor antagonist, MK-4305
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]